SCHEMBL6502277

SCHEMBL6502277

N/N=C(\c1cccc(O)c1)c1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.47
TP53 P04637 6/20 0.47
MAPT P10636 6/20 0.47
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.38
ABCG2 Q9UNQ0 7/20 0.35
EGFR P00533 2/20 0.34
KDR P35968 1/20 0.34
NPC1 O15118 1/20 0.34
CDKN1A P38936 1/20 0.34
PDGFRB P09619 1/20 0.33
CCR2 P41597 1/20 0.33
CCR5 P51681 1/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420021 1.00 SMN1; SMN2 (0.47) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6414695 0.90 PIM1 (0.40) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6414707 0.90 PIM1 (0.40) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6440251 0.87 TP53 (0.41) SMN1; SMN2TP53MAPTPOLBABCG2
SCHEMBL6440257 0.87 TP53 (0.41) SMN1; SMN2TP53MAPTPOLBABCG2
SCHEMBL6435799 0.87 SMN1; SMN2 (0.43) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6435814 0.87 SMN1; SMN2 (0.43) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6412976 0.86 MAPT (0.40) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6412964 0.86 MAPT (0.40) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6431156 0.84 TP53 (0.41) SMN1; SMN2TP53MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 SMN1; SMN2 4369/4885TP53 4485/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.